Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds Up in Study -- WSJ

Dow Jones2026/10/05 16:48

By Xavier Martinez Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21. Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028. This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). (END) Dow Jones Newswires October 05, 2026 12:48 ET (16:48 GMT)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The value of cryptocurrency assets held by the U.S. government has shrunk by $16 billion from last year’s peak.

AiCoin•2026/10/11 03:23

Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"

华尔街见闻•2026/10/11 01:57

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

BeInCrypto•2026/10/10 22:48

The number of stablecoin holders on the Solana chain has surpassed 14 million.

AiCoin•2026/10/10 21:35